NMS·Healthcare·$211M·#253 / 520 in Healthcare
KPTI Karyopharm Therapeutics Inc.
44SPECULATIVE
CATEGORY BREAKDOWN
GROWTH1
QUALITY60
STABILITY52
VALUATION98
GOVERNANCE24
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+0.6%
1
> 50% strong
Gross Margin
Revenue retained after direct costs
95.9%
100
> 50% strong
Cash Runway
Months of cash at current burn rate
10 months
28
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
-79.7%
100
< 25% strong
Price / Sales
Market cap relative to trailing revenue
1.4x
98
< 3x strong
Rule of 40
Growth rate plus operating margin
-62
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
4.5%
36
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+163.1%
0
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE KPTI WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when KPTI's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.